LABP vs. LPTX, CELU, DERM, MNOV, IFRX, MRNS, LTRN, VHAQ, SCYX, and ALRN
Should you be buying Landos Biopharma stock or one of its competitors? The main competitors of Landos Biopharma include Leap Therapeutics (LPTX), Celularity (CELU), Journey Medical (DERM), MediciNova (MNOV), InflaRx (IFRX), Marinus Pharmaceuticals (MRNS), Lantern Pharma (LTRN), Viveon Health Acquisition (VHAQ), SCYNEXIS (SCYX), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical preparations" industry.
Landos Biopharma (NASDAQ:LABP) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
Landos Biopharma currently has a consensus price target of $20.42, indicating a potential downside of 9.12%. Leap Therapeutics has a consensus price target of $11.00, indicating a potential upside of 318.25%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Landos Biopharma.
In the previous week, Leap Therapeutics had 15 more articles in the media than Landos Biopharma. MarketBeat recorded 15 mentions for Leap Therapeutics and 0 mentions for Landos Biopharma. Leap Therapeutics' average media sentiment score of 0.78 beat Landos Biopharma's score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Landos Biopharma has higher revenue and earnings than Leap Therapeutics. Landos Biopharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Landos Biopharma's return on equity of -73.00% beat Leap Therapeutics' return on equity.
49.1% of Landos Biopharma shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 1.3% of Landos Biopharma shares are owned by company insiders. Comparatively, 11.3% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Landos Biopharma has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Leap Therapeutics received 260 more outperform votes than Landos Biopharma when rated by MarketBeat users. Likewise, 68.72% of users gave Leap Therapeutics an outperform vote while only 62.50% of users gave Landos Biopharma an outperform vote.
Summary
Leap Therapeutics beats Landos Biopharma on 12 of the 17 factors compared between the two stocks.
Get Landos Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landos Biopharma Competitors List
Related Companies and Tools
